What Does Truist’s New Analyst Think About Exelixis (EXEL) and Its Next-Generation Cancer Drug?

What Does Truist’s New Analyst Think About Exelixis (EXEL) and Its Next-Generation Cancer Drug?

Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.